MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

Search

Editas Medicine Inc

Отворен

СекторЗдравеопазване

3.99 8.42

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

3.61

Максимум

4.04

Ключови измерители

By Trading Economics

Приходи

23M

-53M

Продажби

-1.1M

3.6M

Марж на печалбата

-1,487.842

Служители

246

EBITDA

23M

-49M

Препоръки

By TipRanks

Препоръки

Неутрален

12-месечна прогноза

+9.3% upside

Дивиденти

By Dow Jones

Следващи печалби

3.11.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

132M

317M

Предишно отваряне

-4.43

Предишно затваряне

3.99

Настроения в новините

By Acuity

100%

0%

358 / 371 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

Editas Medicine Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

2.10.2025 г., 23:30 ч. UTC

Горещи акции

Stocks to Watch: Rumble, Applied Materials, American Outdoor Brands

2.10.2025 г., 21:21 ч. UTC

Печалби

Applied Materials Expects New Export Rule to Hit 2026 Revenue by $600 Million

3.10.2025 г., 00:00 ч. UTC

Придобивния, сливания и поглъщания

Warren Buffett's Berkshire Comes to the Aid of Occidental Petroleum -- Again -- WSJ

2.10.2025 г., 23:40 ч. UTC

Пазарно говорене

Gold Edges Higher, Aided by Risks U.S. Shutdown May Weaken Economy -- Market Talk

2.10.2025 г., 23:39 ч. UTC

Пазарно говорене

Japanese Stocks May Edge Higher, Tracking Wall Street Gains -- Market Talk

2.10.2025 г., 23:29 ч. UTC

Придобивния, сливания и поглъщания

Vistra: Transaction Remains on Track to Close This Qtr or 1Q 2026 >VST

2.10.2025 г., 23:29 ч. UTC

Придобивния, сливания и поглъщания

Vistra: Received Regulatory Approval From FERC for Acquisition of Certain Subsidiaries Owning Seven Natural-Gas Generation Facilities From Lotus Infrastructure Partners >VST

2.10.2025 г., 23:29 ч. UTC

Придобивния, сливания и поглъщания

Vistra: Next Step in Acquisition of Gas Generation Fleet With Approval From Federal Energy Regulatory Commission

2.10.2025 г., 23:00 ч. UTC

Пазарно говорене

Warehouse Needs Time to Restore Credibility With Investors -- Market Talk

2.10.2025 г., 22:54 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Scales's JV Buyout Lauded by Bull -- Market Talk

2.10.2025 г., 22:54 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Global Forex and Fixed Income Roundup: Market Talk

2.10.2025 г., 22:46 ч. UTC

Пазарно говорене

Synlait Milk Loses Bear Following Sale of North Island Assets -- Market Talk

2.10.2025 г., 22:46 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

2.10.2025 г., 21:17 ч. UTC

Придобивния, сливания и поглъщания

Buffett Scores Win in Berkshire's Deal for Occidental Chemicals Unit -- Barrons.com

2.10.2025 г., 20:50 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Energy & Utilities Roundup: Market Talk

2.10.2025 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

2.10.2025 г., 20:49 ч. UTC

Придобивния, сливания и поглъщания

OpenAI's Latest Funding Deal Returns Focus to AI Economy, Lifting U.S. Stocks -- WSJ

2.10.2025 г., 20:00 ч. UTC

Придобивния, сливания и поглъщания

Legrand Signs Definitive Agreement To Acquire Avtron Power Solutions, A Global Provider Of Load Banks & Power Quality Solutions >LR.FR

2.10.2025 г., 19:20 ч. UTC

Пазарно говорене

Natural Gas Snaps Winning Streak Despite Small Inventory Rise -- Market Talk

2.10.2025 г., 19:10 ч. UTC

Пазарно говорене

Bank of Canada to Publish Inflation Dashboard in 2026 -- Market Talk

2.10.2025 г., 19:04 ч. UTC

Пазарно говорене

Oil Futures Extend Losses as Markets Brace for Higher Output -- Market Talk

2.10.2025 г., 18:46 ч. UTC

Придобивния, сливания и поглъщания

Honeywell: Transaction Expected to Improve Annual Free Cash Flow by More Than $100 M Over Next Several Years and Then Decrease Over Time >HON

2.10.2025 г., 18:46 ч. UTC

Придобивния, сливания и поглъщания

Honeywell: Loss Will Be Excluded From Adjusted EPS >HON

2.10.2025 г., 18:46 ч. UTC

Придобивния, сливания и поглъщания

Honeywell: Estimated Impact of Divestiture Will Be One-Time Loss of About $115 M >HON

2.10.2025 г., 18:45 ч. UTC

Придобивния, сливания и поглъщания

Honeywell Will Have No Further Fincl Exposure to the Transferred Liabilities >HON

2.10.2025 г., 18:45 ч. UTC

Придобивния, сливания и поглъщания

Honeywell Utilized Portion of Cash From Resideo Indemnification and Reimbursement Agreement Termination to Fund Delticus Transaction >HON

2.10.2025 г., 18:44 ч. UTC

Придобивния, сливания и поглъщания

Honeywell: Delticus Assumed Full Responsibility for Administering and Resolving All Current and Future Asbestos-Related Claims >HON

2.10.2025 г., 18:44 ч. UTC

Придобивния, сливания и поглъщания

Honeywell and Delticus Contributed About $1.68 B in Cash, as Well as Certain Insurance Assets Related to Legacy Asbestos Liabilities >HON

2.10.2025 г., 18:44 ч. UTC

Придобивния, сливания и поглъщания

Honeywell: Transaction Strengthens Annual Free Cash Flow Generation >HON

2.10.2025 г., 18:43 ч. UTC

Придобивния, сливания и поглъщания

Honeywell Divested All Legacy Bendix Asbestos Liabilities, as Well as Certain Non-Bendix Asbestos Liabilities, to Delticus >HON

Сравнение с други в отрасъла

Ценова промяна

Editas Medicine Inc Прогноза

Ценова цел

By TipRanks

9.3% нагоре

12-месечна прогноза

Среден 3.88 USD  9.3%

Висок 6 USD

Нисък 1 USD

Според 12 анализатори от Wall Street, предложили 12-месечна ценова цел за Editas Medicine Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

12 ratings

5

Купи

5

Задържане

2

Продай

Техническа оценка

By Trading Central

1.33 / 1.54Подкрепа & съпротива

Краткосрочен план

Very Strong Bearish Evidence

Средносрочен план

Neutral Evidence

Дългосрочен план

No Evidence

Настроение

By Acuity

358 / 371 Класиране в Здравеопазване

Настроения в новините

Много силни мечи доказателства

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Editas Medicine Inc

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; collaboration and nonexclusive license agreement with Genevant Sciences to develop Novel mRNA-LNP gene editing therapeuticsand strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
help-icon Live chat